4523 On Other Exchanges
Symbol
Exchange
4523 is not on other exchanges.

eisai co ltd (4523) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EISAI CO LTD (4523)

Related News

No related news articles were found.

eisai co ltd (4523) Related Businessweek News

No Related Businessweek News Found

eisai co ltd (4523) Details

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals worldwide. The company offers Halaven and Lenvima, an anticancer agent; Aloxi, an antiemetic agent; Aricept, a treatment for Alzheimer’s disease; Fycompa, an antiepileptic agent; Methycobal for peripheral neuropathy treatment; BELVIQ for anti-obesity treatment; and LYRICA for neuropathic pain treatment. It also provides Lunesta, a non-benzodiazepine hypnotic agent for insomnia treatment; Pariet, a proton pump inhibitor; HUMIRA, a human anti-TNF-a monoclonal antibody; and epilepsy franchise products, including Zonegran, Zebinix, Fycompa, and Inovelo, which are antiepileptic agents. In addition, the company offers Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome; Actonel, an osteoporosis treatment; and Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment. It has strategic partnerships with Quintiles Inc. for developing six types of anticancer compound candidates; and Epizyme, Inc. to discover, develop, and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically defined patients. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

9,877 Employees
Last Reported Date: 06/17/16
Founded in 1941

eisai co ltd (4523) Top Compensated Officers

Chief Executive Officer, Representative Corpo...
Total Annual Compensation: ¥142.0M
Chief Commercial Officer of Oncology Business...
Total Annual Compensation: ¥130.0M
Vice President, President of Eisai Inc and Ch...
Total Annual Compensation: ¥81.0M
Chief Clinical Officer of Neurology Business ...
Total Annual Compensation: ¥111.0M
Compensation as of Fiscal Year 2016.
eisai co ltd
Eisai Presents Data of Mechanisms of Action Relating to Tumor Immune Response Regarding Combination of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody at AACR 108th Annual Meeting

Eisai Co., Ltd. announced that it has presented the latest research data regarding a mechanism of action that led to increased anti-tumor activity in mouse models which had been dosed with a combination of the in-house developed anticancer agent lenvatinib mesylate (lenvatinib) and an anti-mouse PD-1 antibody, at the American Association for Cancer Research (AACR) 108th Annual Meeting. The results presented at the AACR meeting(1) showed that when syngeneic model mice inoculated with mouse liver cancer, melanoma or colon cancer cell lines were dosed with a combination of lenvatinib (10 mg/kg, once daily) and an anti-mouse PD-1 antibody (500g/mouse, twice a week), lenvatinib alone or an anti-mouse PD-1 antibody alone, a substantial inhibitory effect on tumor growth was observed in mice that had been dosed with the combination therapy compared to the single treatments. Additionally, an increased number of mice in the combination therapy group showed Complete Response (CR) of tumor compared to the single treatment group. Specifically, in the combination therapy group, 7 out of 30 mice showed CR (colon cancer models: 2/10, melanoma models: 2/10, liver cancer models: 3/10), whereas in each single treatment group, 1 out of 30 mice showed CR (colon cancer models: 1/10, melanoma models: 0/10, liver cancer models: 0/10). Furthermore, in the liver cancer mouse model, even when identical cancer cell lines were re-inoculated into mice with complete tumor remission, no in vivo growth was observed. RNA analysis of the cancer tissue and other tests confirmed a reduction in immunosuppressive tumor associated macrophages, a reduction in immunosuppressive signal receptors, and an increase in the ratio of memory T cells in model mice dosed with lenvatinib. This non-clinical research suggested synergistic anti-tumor activity when combining lenvatinib with an anti-mouse PD-1 antibody in the mouse models, based on an immunostimulatory response due to the reduction in tumor associated macrophages and the enhancement of the ratio of memory T cells by lenvatnib. Eisai has positioned oncology as a key therapeutic area of focus and remains committed to providing further evidence for lenvatinib as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

Biocon Partners with Eisai to Market its Anti-Ulcer Drug Rabeprazole in India

Biocon (India) has licensed the rights to market in India Eisai (Japan)'s drug Parit (rabeprazole), which is used for the treatment of duodenal ulcers and gastroesophageal reflux disease (GERD).

Eisai Co., Ltd. Enrollment Commences in Phase III Clinical Study of Eisai's Bace Inhibitor Elenbecestat in Early Alzheimer's Disease in Japan

Eisai Co., Ltd. announced that enrollment has commenced in Japan for MISSION AD1, a global Phase III clinical study of the in-house developed oral beta secretase cleaving enzyme (BACE) inhibitor elenbecestat (development code: E2609) in patients with early Alzheimer's disease (AD). The Phase III clinical trial program for elenbecestat (MISSION AD) consists of two global Phase III clinical studies with the same protocols, MISSION AD1 (Study 301) and MISSION AD2 (Study 302). Both studies are multicenter, placebo-controlled, double-blind, parallel-group Phase III clinical studies aiming to assess the efficacy and safety of elenbecestat for treatment of early AD, including mild cognitive impairment due to AD and a subset of very mild AD, in 1,330 patients with positive biomarkers for brain amyloid pathology. Patients are administered a dosage of 50 mg of elenbecestat daily during the treatment period of 24 months, and the primary endpoint will utilize the Clinical Dementia Rating Sum of Boxes (CDR-SB). MISSION AD1 commenced first in the U.S. in October 2016 and the enrollment has been progressing steadily. MISSION AD2 commenced in the U.S in December 2016, and will commence in Japan shortly. Additionally, in Europe, applications for both clinical studies have been submitted, and preparations to begin are underway.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4523 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4523.
View Industry Companies
 

Industry Analysis

4523

Industry Average

Valuation 4523 Industry Range
Price/Earnings 31.9x
Price/Sales 3.3x
Price/Book 3.0x
Price/Cash Flow 30.5x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact EISAI CO LTD, please visit www.eisai.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.